| Literature DB >> 32209134 |
Xinran Hou1, Yingqi Weng1, Qulian Guo1, Zhuofeng Ding1, Jian Wang1, Jiajia Dai1, Anqi Wei1, Zongbin Song2.
Abstract
Bone cancer pain (BCP) is one of the most common types of chronic cancer pain and its pathogenesis has not been fully understood. Long non-coding RNAs (lncRNAs) are new promising targets in the field of pain research, however, their involvements in BCP have not been reported. In the present study, we established the BCP model by implantation of Walker 256 carcinoma cells into rats' tibial medullary cavity and performed transcriptome sequencing of the ipsilateral lumbar spinal cord to explore changes in expression profiles of lncRNA and mRNA. We identified 1220 differently expressed mRNAs (DEmRNAs) (1171 up-regulated and 49 down-regulated) and 323 differently expressed lncRNAs (DElncRNAs) (246 up-regulated and 77 down-regulated) in BCP model, among which 10 DEmRNAs (5 up-regulated and 5 down-regulated) and 10 DElncRNAs (5 up-regulated and 5 down-regulated) were validated the expression by RT-qPCR. Then, we performed Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis on the expression of DEmRNAs and DElncRNAs, showing that they were mainly enriched in inflammatory and immunologic processes/pathways. Finally, we constructed a co-expression network and a ceRNA network of DEmRNAs and DElncRNAs to exhibit a potential regulatory mechanism of DElncRNAs, directly regulating protein coding gene expression in cis or in trans and indirectly regulating protein coding gene expression by sponging miRNA. In conclusion, our study provided a landscape of dysregulated lncRNA and mRNA in spinal cord of bone cancer pain and detected novel potential targets for treatment in the future.Entities:
Keywords: Bone cancer pain; High-throughput RNA sequencing; Long noncoding RNA; mRNA
Mesh:
Substances:
Year: 2020 PMID: 32209134 PMCID: PMC7092675 DOI: 10.1186/s13041-020-00589-2
Source DB: PubMed Journal: Mol Brain ISSN: 1756-6606 Impact factor: 4.041
Sequences of primers in RT-qPCR
| Gene name | Primer sequences (5′-3′) |
|---|---|
| Cybb | Forward: ACCCAGATGCAAGAAAGAAACAA |
| Reverse: GCAAAGTGATTGGCCTGAGATT | |
| CD74 | Forward: CATCTAAGGGACCCCCATTTC |
| Reverse: CCTAGATCTCAGAGCCCCACAT | |
| Trpm2 | Forward: GAACCAGGGTGGAGGCATCT |
| Reverse: TGACCAGCACCTCCAACATC | |
| Ciita | Forward: TGAGCACCAGACAGTGGAGTGT |
| Reverse: GAGATGCTCCCAGGATGCA | |
| Anxa3 | Forward: CCATGGGAGGGAGAGACAGA |
| Reverse: CTGAAGTATCCTCTCCTCCTTTGTG | |
| NONRATT003582.2 | Forward: AAATTCTTTAGCTCAGCCCTGCTA |
| Reverse: AATGCACGGATCCCATCTTAA | |
| NONRATT004661.2 | Forward: GTATTGCGAACAAAGTCCATCCT |
| Reverse: GCATCCGCGAGCATGTG | |
| NONRATT007487.2 | Forward: AGCCAGTGGGTCACTTGTGTT |
| Reverse: TTCTGCTAAAGTCCGGCTGAA | |
| NONRATT026544.2 | Forward: CCCTCGTCCCTCTGGTCTATG |
| Reverse: GGCTTGCTCAGGGATGCA | |
| NONRATT008764.2 | Forward: GAAGAGTGGGCCGAGAACAA |
| Reverse: AGGCAGACATCAGACACTGC | |
| Crlf1 | Forward: TGCCGGCTAAACTCTGAGGAT |
| Reverse: GTGAGCCTCCAGGTCTGCAT | |
| Cdc42ep2 | Forward: CCCGCCTCCTCTCCAACTAC |
| Reverse: GACCGGTGGGAAGCATACC | |
| Hspa1b | Forward: TGCATGTTCTTTGCGTTTAATCTAA |
| Reverse: AGGTGTTCGCAGGAAGGAAA | |
| AABR07031184.1 | Forward: TGTCCTTTCACGTGCTTGCT |
| Reverse: AGGTGAAAGGCTAAGGCAGACTT | |
| Tnnc2 | Forward: CGCATTGACTTCGACGAGTTT |
| Reverse: GAACACGAAGACCAGCTCCTTAC | |
| MSTRG.12616.2 | Forward: TTCCCAGGCAGCTTCAGACT |
| Reverse: AGCGGGTTGGGTCATCAG | |
| MSTRG.13351.2 | Forward: CACATTGTATATCTGCGCCACAT |
| Reverse: TCAGCCTAGATGCCCAAGAAC | |
| MSTRG.16194.3 | Forward: CCAGTGTCAAATGCATGCTCAT |
| Reverse: CCTGGTCTCTCCCGCTAGAA | |
| MSTRG.16806.2 | Forward: GAAGCGCTTAAGCAAAGTCTCTTC |
| Reverse: CGATACTTTCACCAAACTCTTCCTT | |
| MSTRG.29385.15 | Forward: TCCACTGGCTCAATCATGTGA |
| Reverse: TCCCCAGAAACAGGGATCAA | |
| Gapdh | Forward: TGGCCTCCAAGGAGTAAGAAAC |
| Reverse: GGCCTCTCTCTTGCTCTCAGTATC |
Fig. 1Intratibia inoculation of Walker 256 carcinoma cells caused progressive hyperalgesia and bone destruction. a. Mechanical hypersensitivity arose from 6 days after modeling and lasted to the end of behavioral test, while the mechanical threshold of sham-operated rats kept stable. The data are presented as the mean ± SD, **P < 0.01, ***P < 0.001 compared with sham-operated rats at each timepoint; n = 6, per group. PWMT, paw withdrawal mechanical threshold; BL, baseline; sham, sham-operated group; BCP, bone cancer pain group. b. X-ray examination of left hind paw showed discontinuity and destruction of cortical bone (marked by the arrow) and swelling of soft tissue in proximal tibia of bone cancer pain rats. c. Microscopic examination of tibia slices, by HE staining, showed severe destruction and disarrangement of bone trabecula in bone cancer pain rats, scale bar = 500 μm
Fig. 2Tumor inoculation caused significant changes in mRNA and lncRNA profile detected by transcriptomic high-throughput sequencing. a. Circos plot of genome coverage showed the detected reads were distributed in all chromosomes, similarly in each sample. S1, S2, S3, triplicate sample of the sham-operated group; B1, B2, B3, triplicate sample of bone cancer pain group. b. Heatmap of gene expression correlation between each sample. Pearson’s correlation coefficient within the same biological group was high, indicating intra-group consistency, and the coefficient in different groups was low, indicating inter-group variance. c. Statistic description of detected transcripts overall and differently expressed, respectively. d. Hierarchical cluster analysis of differently expressed mRNA (DEmRNA). The color scale indicates log10FPKM and intensity increases from green to red, which indicates down- and up-regulation, respectively. e. Hierarchical cluster analysis of differently expressed lncRNA (DElncRNA). . volcano plot of DEmRNA, in which vertical lines correspond to 2-fold changes in upregulation or downregulation; horizontal line represents q = 0.05 (p value adjusted by FDR); red points refer to up-regulated mRNAs and blue points refer to down-regulated mRNAs. g. Volcano plot of DElncRNAs
The detailed information of top 20 up-regulated and top 20 down-regulated mRNAs
| gene name | description | log2FC | |
|---|---|---|---|
| Up-regulated | |||
| RT1-Ba | RT1 class II, locus Ba | 6.81 | 0 |
| Cd74 | Cd74 molecule, major histocompatibility complex, class II invariant chain | 6.23 | 0 |
| RT1-Bb | RT1 class II, locus Bb | 6.82 | 0 |
| RT1-Da | RT1 class II, locus Da | 6.79 | 0 |
| Cxcl13 | chemokine (C-X-C motif) ligand 13 | 8.98 | 3.55E-254 |
| RT1-Db1 | RT1 class II, locus Db1 | 4.74 | 1.35E-232 |
| Itgax | integrin, alpha X | 6.15 | 3.62E-200 |
| C3 | complement component 3 | 2.98 | 2.94E-196 |
| Ciita | class II, major histocompatibility complex, transactivator | 8.39 | 2.44E-191 |
| Ncf1 | neutrophil cytosolic factor 1 | 3.65 | 8.10E-173 |
| Lyz2 | lysozyme 2 | 3.92 | 1.48E-161 |
| Cxcl16 | chemokine (C-X-C motif) ligand 16 | 3.88 | 1.53E-160 |
| Clec7a | C-type lectin domain family 7 member A transcript variant 1; Dectin-1; Protein Clec7a | 6.85 | 4.13E-156 |
| Irf8 | interferon regulatory factor 8 | 3.01 | 7.18E-139 |
| Scin | scinderin | > 10 | 7.22E-137 |
| Cxcl9 | chemokine (C-X-C motif) ligand 9 | 5.75 | 5.15E-135 |
| Plek | pleckstrin | 3.04 | 5.72E-132 |
| Ubd | ubiquitin D | 6.71 | 3.27E-131 |
| Ptprc | protein tyrosine phosphatase, receptor type, C | 3.46 | 4.64E-123 |
| Gpnmb | glycoprotein (transmembrane) nmb | 2.88 | 5.98E-123 |
| Down-regulated | |||
| AABR07031184.1 | – | −7.84 | 2.04E-12 |
| Crlf1 | cytokine receptor-like factor 1 | −1.10 | 6.20E-11 |
| Hspa1b | heat shock protein 1B | −1.17 | 3.59E-07 |
| Tnnc2 | troponin C type 2 (fast) | −1.26 | 6.34E-06 |
| F12 | coagulation factor XII (Hageman factor) | −3.45 | 6.14E-05 |
| Mesp2 | mesoderm posterior basic helix-loop-helix transcription factor 2 | −1.74 | 6.18E-05 |
| Hif3a | hypoxia inducible factor 3, alpha subunit | −1.25 | 0.000125375 |
| Hpn | hepsin | −1.25 | 0.000186518 |
| Agtr1a | angiotensin II receptor, type 1a | −1.01 | 0.000198987 |
| Slc7a15 | solute carrier family 7 (cationic amino acid transporter, y + system), member 15 | −3.25 | 0.000249069 |
| Ascl2 | achaete-scute family bHLH transcription factor 2 | −1.81 | 0.00045278 |
| Cdc42ep2 | CDC42 effector protein (Rho GTPase binding) 2 | −1.15 | 0.000468742 |
| Alb | albumin | −1.47 | 0.000614844 |
| Cfap46 | cilia and flagella associated protein 46 | −1.46 | 0.000737338 |
| AC096430.2 | – | −1.19 | 0.000745128 |
| AABR07069524.1 | – | −2.02 | 0.00105327 |
| Ripply2 | ripply transcriptional repressor 2 | −1.22 | 0.001084151 |
| Ucn | urocortin | <−10 | 0.001361414 |
| Eln | elastin | −1.31 | 0.00150543 |
| 7SK | 7SK RNA | −2.66 | 0.001521089 |
The detailed information of top 20 up-regulated and top 20 down-regulated lncRNAs
| LncRNA id | Chromosomal locus | Log2FC | |
|---|---|---|---|
| Up-regulated | |||
| NONRATT029597.2 | 9:92704937–92718218 | > 10 | 1.13E-20 |
| NONRATT025792.2 | 7:54213332–54236613 | > 10 | 2.12E-20 |
| NONRATT013483.2 | 18:56078109–56079084 | 5.98 | 3.89E-20 |
| NONRATT013481.2 | 18:56076008–56076835 | 6.45 | 1.40E-19 |
| NONRATT025583.2 | 7:12490976–12493364 | > 10 | 2.51E-19 |
| NONRATT020861.2 | 4:152968621–152969931 | 4.83 | 3.01E-19 |
| NONRATT008764.2 | 13:55114409–55116581 | 3.89 | 5.05E-15 |
| NONRATT009773.2 | 14:15253248–15258192 | > 10 | 2.17E-13 |
| NONRATT023930.2 | 5:172329170–172330108 | 6.11 | 2.45E-13 |
| MSTRG.29606.1 | 8:58637292–58641625 | 3.35 | 5.65E-13 |
| NONRATT008238.2 | 13:51970515–51971438 | 4.59 | 6.14E-13 |
| NONRATT013482.2 | 18:56077434–56080851 | > 10 | 9.18E-13 |
| NONRATT019710.2 | 3:124458778–124460981 | > 10 | 1.00E-12 |
| NONRATT001368.2 | 1:215660363–215662507 | 4.17 | 1.14E-12 |
| NONRATT022734.2 | 5:153532201–153533094 | 4.82 | 3.52E-12 |
| NONRATT026079.2 | 7:118911458–118913673 | 4.66 | 3.52E-12 |
| NONRATT021744.2 | 4:163393219–163401090 | 5.05 | 4.37E-12 |
| NONRATT007487.2 | 12:38161648–38162391 | 3.32 | 6.42E-12 |
| NONRATT004661.2 | 10:70310274–70312073 | 3.29 | 1.11E-11 |
| NONRATT015068.2 | 2:55981585–55983021 | 3.14 | 1.43E-11 |
| Down-regulated | |||
| MSTRG.29385.15 | 8:45815956–45825522 | <−10 | 2.59E-24 |
| MSTRG.16806.2 | 2:156857842–156861509 | <−10 | 1.13E-20 |
| MSTRG.19227.2 | 3:27166506–27169797 | <− 10 | 5.40E-20 |
| MSTRG.16194.3 | 2:78174449–78184975 | <−10 | 5.40E-12 |
| MSTRG.13351.2 | 17:58405803–58485207 | −5.70 | 5.53E-10 |
| NONRATT002487.2 | 1:87959597–87970073 | <−10 | 6.14E-10 |
| NONRATT020414.2 | 4:71741571–71746773 | <−10 | 5.21E-09 |
| MSTRG.12616.2 | 16:85722254–85740881 | <−10 | 2.57E-08 |
| MSTRG.26149.3 | 6:97231481–97233020 | <−10 | 3.66E-08 |
| MSTRG.9921.3 | 14:66037977–66050713 | <−10 | 3.84E-08 |
| MSTRG.32467.2 | X:13336182–13347008 | <−10 | 6.21E-08 |
| MSTRG.11320.2 | 15:77416838–77420559 | <−10 | 1.37E-07 |
| NONRATT016515.2 | 2:183503246–183519420 | <−10 | 8.07E-07 |
| NONRATT016788.2 | 2:211344017–211344442 | −6.21 | 9.85E-07 |
| NONRATT005011.2 | 10:97680659–97683273 | −6.37 | 1.41E-06 |
| NONRATT005584.2 | 10:56339278–56341596 | −4.82 | 1.52E-06 |
| NONRATT005012.2 | 10:97683239–97684709 | −2.98 | 2.52E-06 |
| MSTRG.4193.2 | 10:9842392–9844018 | −5.06 | 2.83E-06 |
| NONRATT012007.2 | 16:54083152–54087424 | <−10 | 3.09E-06 |
| MSTRG.4440.2 | 10:24800650–24814515 | −4.85 | 3.59E-06 |
Fig. 3RT-qPCR validation of partial DEmRNAs and DElncRNAs on another batch of samples independent of the ones used for RNA-seq (n = 6 per group). a. The expression level of up-regulated mRNAs, with gene name on each bar graph. b. The expression level of down-regulated mRNAs. c. The expression level of up-regulated lncRNAs. d. The expression level of down-regulated lncRNAs. **P < 0.01, ***P < 0.001, compared with sham-operated rats
Fig. 4GO enrichment and KEGG enrichment analysis for DEmRNAs and DElncRNAs. a. GO enrichment of DEmRNAs showing the top 10 terms (according to P value) in three types of GO terms, biological process (shown in red), cellular component (shown in green) and molecular function (shown in blue). b. GO enrichment of potential target of DElncRNA. c. KEGG enrichment analysis for DEmRNAs showing the top 30 pathways, with the size of bubble indicating the number of enriched mRNAs, the color indicating p value and position indicating rich factor. d. KEGG enrichment of potential target of DElncRNA
Fig. 5Comparative analysis, Protein-protein interaction (PPI) network and functional enrichment network construction of top 200 DEmRNAs. a. The Circos plot showing how genes from the input gene lists overlap, in which on the outside the red arch represents the 58 unique differential genes reported by Hui Du et al., the blue arch representing 173 unique differential genes reported by Michael Costigan et al., and the green arch representing our top 200 unique differential genes; on the inside dark orange color represents the genes that appear in multiple lists and light orange color represents genes that are unique to that gene list; and purple lines link the same genes that are shared by multiple gene lists, blue lines linking the different genes where they fall into the same ontology term (the terms statistically significantly enriched and with size no larger than 100). b. PPI network constructed by the top 200 DEmRNA-coding protein. The color scale of the node indicates the number of connectivity with other nodes and the thickness of the edge indicates the combined score of the interaction. The clusters in light yellow frame were the top four subnetworks calculated by MCODE. c. Functional enrichment network constructed by nodes representing terms with the best p values from each of the 20 clusters, with the constraint that there are no more than 15 terms per cluster and no more than 250 terms in total and edges connecting terms with a similarity > 0.3
Fig. 6Co-expression network of DElncRNA and their potential target mRNA with 131 lncRNA and 137 mRNA nodes and 350 edges. The color scale indicates log2FC, and intensity increases from green to red, which indicates down- and up-regulation, respectively. The ellipse node indicates lncRNA and the rhombus node indicates mRNA. The blue arrow indicates lncRNA regulating mRNA in cis, while the gray arrow indicating in trans
Fig. 7CeRNA network constructed by 34 DElncRNA nodes, 13 miRNA nodes and 192 DEmRNA nodes with 287 edges. The ellipse node indicates lncRNA, while the arrow node indicating miRNA, and the rhombus node indicating mRNA